Next-Generation Mucopolysaccharidosis Type I Treatment System

A novel, next-generation treatment system for Mucopolysaccharidosis Type I, leveraging cutting-edge gene editing, RNA-based therapies, and advanced delivery systems to provide a more effective, sustainable, and patient-centric solution.

Current treatments for Mucopolysaccharidosis Type I, such as enzyme replacement therapy and bone marrow transplant, have limitations, including invasive procedures, variable efficacy, and high costs. The original patent's method, while an improvement, still relies on AAV vectors and may not provide sustained expression of the iduronidase enzyme. The new inventive concept addresses these limitations by introducing a paradigm shift in MPS I treatment, offering a more ambitious and forward-thinking solution.

The next-generation treatment system comprises four key components: 1) a gene editing module utilizing a CRISPR-Cas9 system and a novel guide RNA to integrate a corrective copy of the iduronidase transgene into the albumin locus of hepatocytes in vivo; 2) a self-replicating RNA molecule encoding the iduronidase enzyme, capable of sustained expression in vivo; 3) a hybrid promoter-based gene therapy vector enabling high-level, tissue-specific expression of the iduronidase enzyme; and 4) an implantable device containing a gene editing module and a source of hepatocytes, or a nanoparticle-based delivery system targeting the liver and enabling sustained release of the iduronidase enzyme. These components work in concert to provide a continuous and stable source of the iduronidase enzyme, addressing the root cause of MPS I.

The new claims introduce a novel, non-obvious combination of gene editing, RNA-based therapies, and advanced delivery systems, which represents a significant departure from the original patent's AAV vector-based approach. The use of CRISPR-Cas9, self-replicating RNA molecules, and hybrid promoters enables a more targeted, efficient, and sustainable treatment of MPS I.

Alternative embodiments of the inventive concept could include the use of different gene editing tools, such as base editing or prime editing, or the incorporation of additional therapeutic modalities, such as small molecule therapies or antisense oligonucleotides. Variations of the delivery system could include the use of different nanoparticle materials or targeting strategies.

The next-generation treatment system has the potential to revolutionize the treatment of Mucopolysaccharidosis Type I, offering a more effective, patient-centric, and cost-efficient solution. The market potential is significant, with an estimated global market size of over $1 billion by 2025. The technology could also be applied to other lysosomal storage diseases, expanding the market potential further.